Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 10/20 | 0.62 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.62 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.62 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.48 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 3/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.48 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5770200 | 0.86 | MAPK13 (0.63) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL5769239 | 0.86 | MAPK13 (0.73) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL5773271 | 0.84 | MAPK13 (0.70) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL5769932 | 0.84 | MAPK13 (0.58) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| Acetamide SCHEMBL27744839 | 0.83 | MAPK13 (0.69) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL5769642 | 0.83 | MAPK13 (0.74) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL5770167 | 0.83 | MAPK13 (0.74) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL27518882 | 0.83 | MAPK13 (0.63) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL5772456 | 0.82 | MAPK13 (0.65) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL5768771 | 0.82 | MAPK13 (0.65) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038991-A1 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2004-02-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038991-A1 | Imidazolyl-cyclic acetals | CBR1, LBR, CBR3 | MAPK13 1610/4885MAPK12 2766/4885MAPK11 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.